Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CEO and President

Chief Manufacturing Officer

Chief Scientific Officer

Principal Accounting Officer

Chief Executive Officer

Chief Financial Officer

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Assembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B vi...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-30	Premium	sold	Premium	Premium	Premium	CEO and President
2024-04-30	Premium	sold	Premium	Premium	Premium	Chief Manufacturing Officer
2024-04-29	Premium	acquired	Premium	Premium	Premium	CEO and President
2024-04-29	Premium	acquired	Premium	Premium	Premium	Chief Manufacturing Officer
2024-04-29	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	Chief Manufacturing Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	Principal Accounting Officer
2024-04-01	Premium	sold	Premium	Premium	Premium	-
2024-04-01	Premium	sold	Premium	Premium	Premium	CEO and President
2024-03-29	Premium	acquired	Premium	Premium	Premium	Principal Accounting Officer
2024-03-27	Premium	sold	Premium	Premium	Premium	CEO and President
2024-01-18	Premium	bought	Premium	Premium	Premium	-
2024-01-17	Premium	bought	Premium	Premium	Premium	-
2023-11-21	Premium	bought	Premium	Premium	Premium	-
2023-11-20	Premium	bought	Premium	Premium	Premium	-
2023-11-17	Premium	sold	Premium	Premium	Premium	Chief Manufacturing Officer
2023-10-03	Premium	sold	Premium	Premium	Premium	Chief Manufacturing Officer
2023-10-03	Premium	sold	Premium	Premium	Premium	CEO and President
2023-10-03	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-10-02	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2023-10-02	Premium	acquired	Premium	Premium	Premium	CEO and President
2023-10-02	Premium	acquired	Premium	Premium	Premium	Chief Manufacturing Officer

ASMB - Assembly Biosciences Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for ASMB